Answers are grounded in this paper and cite their sources.
Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects. An influence on overall survival has not yet been shown. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT00934544.).
No takes yet. Share an insight, caveat, or question.
Harrison et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: